129 related articles for article (PubMed ID: 37828647)
1. Systemic therapies at the end of life vary by patient and practice: Whether or not patients with cancer at the end of life received systemic therapies, including immunotherapies, depended partly on their race, insurance type, and the practice at which they were treated, but are decisions based on these factors in the patients' best interests?
Nierengarten MB
Cancer; 2023 Nov; 129(21):3354-3355. PubMed ID: 37828647
[No Abstract] [Full Text] [Related]
2. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting.
Canavan M; Wang X; Ascha M; Miksad R; Showalter TN; Calip G; Gross CP; Adelson K
J Clin Oncol; 2023 Oct; 41(30):4729-4738. PubMed ID: 37339389
[TBL] [Abstract][Full Text] [Related]
3. Decision making in the end-of-life care of patients who are terminally ill with cancer - a qualitative descriptive study with a phenomenological approach from the experience of healthcare workers.
Luna-Meza A; Godoy-Casasbuenas N; Calvache JA; Díaz-Amado E; Gempeler Rueda FE; Morales O; Leal F; Gómez-Restrepo C; de Vries E
BMC Palliat Care; 2021 May; 20(1):76. PubMed ID: 34049535
[TBL] [Abstract][Full Text] [Related]
4. Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients.
Brom L; Pasman HR; Widdershoven GA; van der Vorst MJ; Reijneveld JC; Postma TJ; Onwuteaka-Philipsen BD
PLoS One; 2014; 9(6):e100435. PubMed ID: 24964036
[TBL] [Abstract][Full Text] [Related]
5. Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients' involvement in specific therapies decision-making.
Beaussant Y; Mathieu-Nicot F; Pazart L; Tournigand C; Daneault S; Cretin E; Godard-Marceau A; Chassagne A; Trimaille H; Bouleuc C; Cuynet P; Deconinck E; Aubry R
BMC Palliat Care; 2015 Nov; 14():61. PubMed ID: 26572617
[TBL] [Abstract][Full Text] [Related]
6. Medical decisions concerning the end of life for cancer patients in three Colombian hospitals - a survey study.
de Vries E; Leal Arenas FA; van der Heide A; Gempeler Rueda FE; Murillo R; Morales O; Diaz-Amado E; Rodríguez N; Gonzalez BJ; Castilblanco Delgado DS; Calvache JA
BMC Palliat Care; 2021 Oct; 20(1):161. PubMed ID: 34657613
[TBL] [Abstract][Full Text] [Related]
7. Physician reports of medication use with explicit intention of hastening the end of life in the absence of explicit patient request in general practice in Belgium.
Meeussen K; Van den Block L; Bossuyt N; Echteld M; Bilsen J; Deliens L
BMC Public Health; 2010 Apr; 10():186. PubMed ID: 20380710
[TBL] [Abstract][Full Text] [Related]
8. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
9. Decisions about life-sustaining measures in children: in whose best interests?
Cornfield DN; Kahn JP
Acta Paediatr; 2012 Apr; 101(4):333-6. PubMed ID: 22103464
[TBL] [Abstract][Full Text] [Related]
10. Hastening death in end-of-life care: a survey of doctors.
Seale C
Soc Sci Med; 2009 Dec; 69(11):1659-66. PubMed ID: 19837498
[TBL] [Abstract][Full Text] [Related]
11. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.
Busolo D; Woodgate R
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011
[TBL] [Abstract][Full Text] [Related]
12. Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients.
Kim JS; Yoo SH; Choi W; Kim Y; Hong J; Kim MS; Park HY; Keam B; Heo DS
Cancer Res Treat; 2020 Jul; 52(3):917-924. PubMed ID: 32204581
[TBL] [Abstract][Full Text] [Related]
13. End-of-life decisions in cancer care.
Price KJ; Kish SK
Crit Care Clin; 2001 Jul; 17(3):805-11. PubMed ID: 11525059
[TBL] [Abstract][Full Text] [Related]
14. The impact of regional culture on intensive care end of life decision making: an Israeli perspective from the ETHICUS study.
Ganz FD; Benbenishty J; Hersch M; Fischer A; Gurman G; Sprung CL
J Med Ethics; 2006 Apr; 32(4):196-9. PubMed ID: 16574871
[TBL] [Abstract][Full Text] [Related]
15. Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life.
Won YW; Kim HJ; Kwon JH; Lee HY; Baek SK; Kim YJ; Kim DY; Ryu H
Cancer Res Treat; 2021 Oct; 53(4):908-916. PubMed ID: 34082495
[TBL] [Abstract][Full Text] [Related]
16. Nurses' decision-making about cancer patients' end-of-life skin care in Wales: an exploratory mixed-method vignette study protocol.
Samuriwo R; Lovell-Smith C; Anstey S; Job C; Hopkinson J
BMJ Open; 2020 Jul; 10(7):e034938. PubMed ID: 32624470
[TBL] [Abstract][Full Text] [Related]
17. Protocol for the Assessment of Patient Capacity to Make End-of-Life Treatment Decisions.
Stuart RB; Thielke S
J Am Med Dir Assoc; 2018 Feb; 19(2):106-109. PubMed ID: 29287691
[TBL] [Abstract][Full Text] [Related]
18. End-of-life decision making in Taiwan: healthcare practice is rooted in local culture and laws that should be adjusted to patients' best interests.
Tang ST
J Med Ethics; 2013 Jun; 39(6):387-8. PubMed ID: 22679104
[TBL] [Abstract][Full Text] [Related]
19. Best interests at end of life: an updated review of decisions made by the Consent and Capacity Board of Ontario.
Chidwick P; Sibbald R; Hawryluck L
J Crit Care; 2013 Feb; 28(1):22-7. PubMed ID: 23228726
[TBL] [Abstract][Full Text] [Related]
20. End-of-life decision-making of terminally ill cancer patients in a tertiary cancer center in Shanghai, China.
Gu X; Chen M; Liu M; Zhang Z; Cheng W
Support Care Cancer; 2016 May; 24(5):2209-2215. PubMed ID: 26567116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
